EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Frequency and outcome of metaplasia in needle biopsies of prostate and its relation with clinical findings



Frequency and outcome of metaplasia in needle biopsies of prostate and its relation with clinical findings



Urology Journal 6(2): 109-113



Metaplasia is a reversible change in which one adult cell type is replaced by another adult cell type. Our aim was to determine the frequency and outcome of metaplasia in specimens from needle biopsies of the prostate and its relation with clinical findings. Among 1566 prostate specimens referred to 2 pathology centers of Tehran, we studied on cases with a diagnosis of metaplasia, during a 2-year period. The clinical and laboratory data of the patients with metaplasia were collected, and they were followed-up for 2 years. Age, serum total and free prostate-specific antigen levels, ultrasonography findings, and results of digital rectal examination were recorded at baseline and the follow-up period. Ten prostate specimens (0.6%) had metaplasia, of which 6 were transitional and 4 were squamous metaplasia. Serum total PSA levels ranged from 0.7 ng/mL to 14.5 ng/mL, and free PSA levels ranged from 0.1 ng/mL to 1.3 ng/mL in the patients with metaplasia. None of the patients developed carcinoma of the prostate during the 2-year follow-up, and no significant changes were seen in the follow-up studies. Metaplasia of the prostate are often associated with BPH. Clinical findings on DRE and TRUS resemble those found in benign lesions of the prostate, such as BPH. We found no sign of developing malignancy in our 2-year follow-up. However, in the differential diagnosis of this benign lesion, malignant lesions, such as squamous cell carcinoma or urothelial transitional cell carcinoma, should also be taken into consideration.

(PDF 0-2 workdays service: $29.90)

Accession: 053301845

Download citation: RISBibTeXText

PMID: 19472129



Related references

Fat invasion in ten-core prostate needle biopsies: incidence, biopsy and clinical findings. International Braz J Urol 30(4): 346-347, 2005

The classification frequency and clinical significance of atypical prostate hyperplasia aph in otherwise benign prostatic needle biopsies bx. Journal of Urology 137(4 PART 2): 193A, 1987

Post-radiation prostate needle biopsies in 121 patients with and without neoadjuvant hormonal therapy Histologic grading and clinical outcome. Laboratory Investigation 80(1): 111A, 2000

Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes Study of 15,753 prostate needle biopsies in 332 institutions. Archives of Pathology & Laboratory Medicine 123(8): 687-692, 1999

Histopathology reports of findings of prostate needle biopsies. Individual treatment. Der Urologe. Ausg. A 52(2): 226-239, 2013

Stage A1 prostate cancer: follow-up with digital rectal exploration, prostate markers, fine-needle aspiration, ultrasonographically guided needle biopsy and biopsies of the residual prostate with resectoscope. European Urology 25(2): 116-118, 1994

False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. American Journal of Surgical Pathology 34(1): 35-43, 2010

Histologic findings on prostate needle core biopsies following cryotherapy as monotherapy for prostatic adenocarcinoma. Human Pathology 44(5): 867-872, 2013

Systematic finger guided transrectal needle biopsies of the prostate--alternative to TRUS guided biopsies in clinical practice. Canadian Journal of Urology 8(5): 1365-70; Discussion 1371, 2001

Correlation between prostate needle biopsies and radical prostatectomy specimens: can we predict pathological outcome?. Pathology 40(6): 586-591, 2008

Pathologic findings in patients with targeted magnetic resonance imaging-guided prostate needle core biopsies. International Journal of Clinical and Experimental Pathology 8(9): 9790-9795, 2016

Comparison of dna flow cytometry and cytologic pathology of prostate needle aspirates to prostate needle biopsies. Journal of Urology 137(4 PART 2): 352A, 1987

Histopathologic review of previously negative prostatic core needle biopsies following a new diagnosis of adenocarcinoma of the prostate by core needle biopsies: implications for quality assurance programs. Clinical Medicine. Pathology 1: 77-81, 2008

Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome. Bju International 108(8): 1356-1362, 2011

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. Bmc Genomics 14(): 690-690, 2014